MedTrace Logo

Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases

NCT02426879 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-09-30

No results posted yet for this study

Summary

There is no world-wide consensus on the oncological benefit versus increased morbidity associated with three field lymphadenectomy in patients with esophageal cancer and cervical lymph node metastases. In Asian countries, esophagectomy is commonly combined with a three field lymphadenectomy, including resection of cervical, thoracic and abdominal lymph nodes. However, in Western countries patients with cervical lymph node metastases are generally precluded from curative treatment.

Conditions

Interventions

PROCEDURE

esophagectomy with three-field lymphnode dissection

robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Richard V Hillegersberg, Prof Dr · UMCU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-11
Primary Completion
2021-01-25
Completion
2021-01-25

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426879 on ClinicalTrials.gov